Trillium Therapeutics shares soar on Pfizer’s $2.26B deal

Trillium Therapeutics shares soar on Pfizer’s $2.26B deal Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies. https://ift.tt/382GaOd https://ift.tt/2WgpIrf Markets August 23, 2021 at 04:56PM